Table 2.
First author, publication year | Assay method | Cutoff point | Case number
|
OS
|
DFS/RFS/PFS
|
|||
---|---|---|---|---|---|---|---|---|
High expression | Low expression | HR (95% CI) (U/M) | p-value | HR (95% CI) (U/M) | p-value | |||
Zhu, 201710 | IHC | IRS scores ≥3 (range of 0–12) | 65 | 139 | 0.302 (0.184–0.497)M | <0.001 | NM | NM |
Lu, 201612 | IHC | IRS scores ≥3 (range of 0–12) | 134 | 191 | 0.648 (0.492–0.854)M | 0.002 | NM | NM |
Singh, 201611 | qRT-PCR | NM | 46 | 29 | 0.66 (0.26–1.68)Ue | 0.047 | NM | NM |
Guo, 201516,a | IHC | >10% of tumor cells stained | 28 | 100 | 1.07 (0.22–5.24)Ue | <0.05 | NM | NM |
Guo, 201516,b | qRT-PCR | NM | 40 | 88 | 0.62 (0.19–1.98)Ue | <0.05 | NM | NM |
Wu, 201532 | IHC | IRS scores ≥3 (range of 0–12) | 56 | 118 | 0.430 (0.269–0.687)M | <0.001 | NM | NM |
Han, 201536 | IHC | IRS scores ≥3 (range of 0–12) | 137 | 188 | 0.617 (0.462–0.823)M | 0.001 | NM | NM |
Yu, 201413 | IHC | IRS scores ≥3 (range of 0–12) | 34 | 49 | 0.226 (0.094–0.545)M | 0.001 | 0.278 (0.119–0.647)M | 0.003 |
Kwon, 201419 | IHC | .0% of tumor cells stained | 98 | 546 | 1.513 (1.057–2.165)M | 0.024 | f | f |
Tang, 201414,c | IHC | IRS scores ≥8 (range of 0–12) | 114 | 303 | 0.42 (0.29–0.63)M | 0.0000147 | NM | NM |
Tang, 201414,d | IHC | IRS scores ≥8 (range of 0–12) | 114 | 303 | 0.59 (0.36–0.96)M | 0.029 | NM | NM |
Zhang, 201337 | IHC | Accumulated points ≥80 | 52 | 48 | 0.54 (0.27–1.05)Ue | NM | NM | NM |
Zhang, 201338 | WB | NM | 43 | 43 | 0.36 (0.17–0.77)Ue | NM | NM | NM |
Wu, 201215 | IHC | IRS scores >1 (range of 0–12) | 19 | 31 | 0.039 (0.007–0.236)M | 0.00 | NM | NM |
Knoener, 201233 | IHC | IRS scores ≥3 (range of 0–12) | 168 | 103 | 0.77 (0.55–1.07)Ue | 0.2305 | NM | NM |
Guo, 200939 | IHC | >10% of tumor cells stained | 21 | 59 | 0.81 (0.28–2.32)Ue | 0.022 | NM | NM |
Protzel, 200834 | IHC | >50% of tumor cells stained | 17 | 13 | 0.34 (0.02–4.90)Ue | 0.0042 | NM | NM |
Miyazaki, 200540 | IHC | Ki index ≥39 | 48 | 43 | 0.48 (0.22–1.03)Ue | 0.0023 | NM | NM |
Leavey, 200517 | IHC | NM | 16 | 31 | 1.14 (0.27–4.81)Ue | 0.28 | 0.99 (0.35–2.85)Ue | 0.24 |
Farhadieh, 200441 | IHC | >10% of tumor cells stained | 15 | 42 | 0.52 (0.27–1.01)M | 0.053 | 0.4 (0.2–0.8)M | 0.009 |
Goncharuk, 200442 | IHC | Median | 77 | 27 | 0.47 (0.23–0.97)Ue | 0.034 | NM | NM |
Su, 200450 | IHC | >50% of tumor cells stained | 54 | 33 | NM | NM | 0.255 (0.111–0.588)M | 0.0013 |
Hashida, 200318 | IHC | Scores ≥120 (range of 0–300) | 63 | 83 | 0.903 (0.297–2.747)M | 0.858 | 1.054 (0.431–2.577)M | 0.909 |
Imai, 200243 | qRT-PCR | NM | 25 | 18 | 0.51 (0.06–4.38)Ue | NM | NM | NM |
Schindl, 200144 | IHC | Scores ≥4 (range of 3–7) | 48 | 59 | 0.45 (0.22–0.92)M | 0.0282 | 0.3 (0.09–0.93)M | 0.0372 |
Miyazaki, 200045 | IHC | >10% of tumor cells stained | 36 | 19 | 0.41 (0.17–1.00)Ue | 0.024 | NM | NM |
Yang, 200046 | IHC | >5% of tumor cells stained | 36 | 36 | 0.72 (0.20–2.61)Ue | NM | NM | NM |
Sho, 199847 | IHC | >50% of tumor cells stained | 15 | 25 | 1.16 (0.29–4.64)Ue | 0.018 | NM | NM |
Huang, 199848 | IHC | HSCORE >50 | 44 | 65 | 0.442 (0.109–1.789)M | 0.2528 | 0.360 (0.149–0.870)M | 0.0234 |
Higashiyama, 199735 | IHC | >50% of tumor cells stained | 65 | 135 | 0.700 (0.502–0.976)M | 0.037 | f | f |
Adachi, 199649 | qRT-PCR | Gene conservation rate value >1.2 | 35 | 116 | 0.416 (0.175–0.986)M | 0.046 | NM | NM |
Notes: The source of HR and 95% CI was extracted from survival curves or article reports.
Data extracted from one study due to different assay method (IHC and qRT-PCR).
Data extracted from one study due to different follow-up time (120 and 60 months).
HR calculated from survival curves.
Excluded due to its heterogeneity and publication bias.
Abbreviations: IHC, immunohistochemistry; qRT-PCR, quantitative reverse transcription-polymerase chain reaction; WB, western-blot; NM, not mentioned; IRS, immunoreactivity score; HSCORE, the intensity and respective percentage cells that stain at each intensity were multiplied to reach a HSCORE that ranged from 0 to 300; OS, overall survival; DFS, disease-free survival; RFS, recurrence-free survival; PFS, progression-free survival; SC, survival curve; HR, hazard ratio; CI, confidence interval; U, univariate analysis; M, multivariate analysis.